| Name | Title | Contact Details |
|---|
Chamberlin Edmonds is committed to setting and achieving high standards of ethical conduct. We strive to maintain an ethical, compliant, safe workplace, as well as treating all of our business partners (including hospitals, patients, and government
At California Hospital Association (CHA), we collaborate with our members to provide strong and effective representation and advocacy to advance the interests of California hospitals, patients and communities. CHA is a trusted resource, working with members to achieve legislative, regulatory, and legal accomplishments at the state and federal level. Based in Sacramento, CHA is the statewide leader representing the interests of more than 400 hospitals and health systems in California.
MedImpact Healthcare Systems, Inc. is the nation’s largest privately held pharmacy benefit management (PBM) company, serving health plans, self-funded employers and government entities. Our business model is unique: avoiding conflicts of interest by not dispensing drugs. MedImpact is focused on effectively managing client pharmacy benefits to facilitate better trend management and improved outcomes. We work with clients to direct prescribing to the lowest-net-cost, medically appropriate drug. Our number one goal is client satisfaction by providing flexible solutions and consumer-driven products with a focus on lowest net cost and quality outcomes.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.
Wound Management Technologies is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.